Samsung Biologics shares have surged over 10% following the announcement of its second-quarter earnings, which met market expectations.
As of 2:50 PM on July 24, Samsung Biologics was trading at 1,524,000 won, up 145,000 won (10.51%) from the previous trading day, according to the Korea Exchange.
The company reported consolidated revenue of 1.32 trillion won and an operating profit of 586.4 billion won for the second quarter of this year, marking increases of 30% and 23%, respectively, compared to the same period last year.
Samsung Biologics attributed its robust growth to the full operation of its first through fourth plants and favorable exchange rates. Despite the upfront costs associated with its fifth plant and the Rockville facility in the U.S., the operating profit margin remained above 40%.
For the first half of the year, cumulative revenue reached 2.578 trillion won, and operating profit was 1.1672 trillion won, reflecting increases of 28% and 29%, respectively, compared to the same period last year.
Kim Seon-a, a researcher at Hana Securities, stated, "The second-quarter results are in line with market consensus. With revenue from the Rockville plant expected to be reflected starting in the third quarter and continued benefits from exchange rates, achieving an annual revenue growth rate of over 20% is feasible."
She added, "While the initial operations of the fifth plant and the Rockville facility may impact short-term profitability due to upfront costs, these expenses are part of the process of securing clients and diversifying the business. In the medium to long term, it is important to focus on expanding production capacity (CAPA) and strengthening business capabilities."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.